RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Science & Technology: The Current Regulatory Landscape for Cardiac & Cardiovascular Safety Assessme

Science & Technology: The Current Regulatory Landscape for Cardiac & Cardiovascular Safety Assessments: Part I

Posted 01 January 2011 | By Raymond A. Huml, MS, DVM, RACJ. Rick Turner

Cardiac and cardiovascular safety concerns continue to be leading reasons for drug failures during development and marketing, and have led to product withdrawals. Several high-profile marketing withdrawals involved drugs for non-life-threatening diseases. For example, in 1998, terfenadine (Seldane), an antihistamine used for allergies, was removed from the US market following deaths from a form of polymorphic ventricular tachycardia called Torsades de Pointes (TdP)-a French term, which literally translated, means "twisting of the points." In 2000, cisapride (Propulsid), a very effective and successful gastroprokinetic agent marketed by Janssen/Ortho for gastroesophageal reflux disease (GERD), to speed gastric emptying while increasing esophageal sphincter tone, was withdrawn from the market after a warning from the US Food and Drug Administration (FDA) to prescribers regarding the product's propensity to prolong cardiac repolarization. Regulatory concern over drug-induced TdP led to preclinical and clinical draft guidance documents in 2002, which were finalized in 2005 with the publication of the cornerstone International Conference on Harmonisation (ICH) guidelines "S7B"1 and"E14,"2 respectively. E14 is discussed later.

 

© 2022 Regulatory Affairs Professionals Society.